All In Biotech

Drug Trial Radar · NCT06967519

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline.

Conditions

  • Malaria
  • Hiv

Interventions

  • Artemether-lumefantrine (AL)Drug

    Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine

  • artesunate-amodiaquine (AS-AQ)Drug

    Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Body Mass Index (BMI)Time frame: baseline and 2 years
  2. Drug pharmacokinetic (PK) exposureTime frame: baseline up to 2 years
  3. Drug pharmacokinetic exposureTime frame: baseline up to 2 years
  4. Recurrence rate of malariaTime frame: 28 days and 42 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Baylor- Uganda

    Kampala, Uganda · Recruiting

  • Infectious Disease Research Collaboration (IDRC)

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.